Cumulative Exposure to Lead in Relation to Cognitive Function in Older Women by Weuve, Jennifer et al.
574  v o l u m e  117 | n u m b e r 4 | April 2009  •  Environmental Health Perspectives
Research
Impaired cognition and cognitive decline in 
older age are associated with heightened risks 
of subsequent physical disability (Greiner et al. 
1996; McGuire et al. 2006; Raji et al. 2004) 
and hospitalization (Chodosh et al. 2004), 
even after control for general health status. 
Moreover, small decrements in cognition are 
strong predictors of eventual development of 
dementia (Blacker et al. 2007; Elias et al. 2000; 
Kawas et al. 2003; Linn et al. 1995; Morris 
et al. 2001; Small et al. 2000). For example, 
in studies of non  demented older adults, those 
who eventually developed cognitive impair-
ment or dementia had average cognitive test 
scores at baseline that were only 0.15–0.9 stan-
dard units below the mean scores among indi-
viduals who remained cognitively intact (Linn 
et al. 1995; Morris et al. 2001; Small et al. 
2000). The early, pre-clinical stages of disease 
represented by small cognitive decrements may 
be most amenable to intervention. The identi-
fication of modifiable risk factors for cognitive 
decline may provide important clues for delay-
ing or even preventing dementia. 
These modifiable risk factors potentially 
include exposures to environmental toxicants, 
and among the most historically pervasive 
and well-established neurotoxic pollutants is 
lead. Lead has been shown to be neurotoxic at 
progressively lower doses in children (Koller 
et al. 2004) and at high doses in occupationally 
exposed adults (Fiedler et al. 2003; Schwartz 
and Stewart 2000; Shih et al. 2007). Because 
lead is difficult to excrete (Agency for Toxic 
Substances and Disease Registry 2006), older 
adults, by virtue of their longer life spans, gen-
erally have accrued higher lead exposures than 
younger adults, whether these exposures origi-
nated from occupational or, more commonly, 
non  occupational sources (Vig and Hu 2000). 
Comparatively little research has evaluated the 
relation of cumulative lead exposure to cogni-
tive function and decline in older adulthood, 
although a growing body of research on this 
topic has emerged over the past decade. These 
studies generally have found inverse associa-
tions between indices of lead exposure and 
both cognitive function and change in cog-
nitive function (Shih et al. 2007). However, 
women are under  represented in this research. 
For example, in their review of studies investi-
gating cumulative lead exposure and cognitive 
outcomes in adults, Shih et al. (2007) identi-
fied 21 studies, and in 16 of these studies, over 
80% of participants were men. None of the 
studies reported results specific to women.
The measure of lead exposure is a critical 
feature of any study that examines lead expo-
sure and cognition among older, community-
exposed women in the United States Blood 
lead level is a gauge of recent lead dose, in 
contrast to concentration of lead in bone, 
which is an integrative measure of lead expo-
sure over many years, in addition to being an 
endogenous source of lead (Hu et al. 2007). 
Thus, blood lead levels are likely to be less 
informative than bone lead about cumulative 
exposures in an environment characterized by 
low lead content in the present but relatively 
high content in the past, such as that in the 
United States after the phase-out of leaded 
gasoline in the 1980s.
Therefore, to better characterize the effects 
of recent and cumulative lead exposure on cog-
nition in older women, we conducted a pro-
spective study of both bone and blood lead 
levels in relation to cognitive function in a 
cohort of older, community-exposed women, 
hypothesizing that measures of lead exposure 
would be related to worse performance on the 
cognitive tests, but that associations would 
be stronger for bone lead levels, measures of 
cumulative exposure.
Materials and Methods
Study population. The Nurses’ Health Study 
(NHS) began in 1976 when 121,700 regis-
tered nurses, 30–55 years of age and living 
in 11 U.S. states, returned a questionnaire 
on their medical history and health-related 
behaviors (Colditz et al. 1997). Since then, 
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Ba c k g r o u n d: Recent data indicate that chronic low-level exposure to lead is associated with 
  accelerated declines in cognition in older age, but this has not been examined in women.
oB j e c t i v e: We examined biomarkers of lead exposure in relation to performance on a battery of 
cognitive tests among older women.
Me t h o d s : Patella and tibia bone lead—measures of cumulative exposure over many years—and 
blood lead, a measure of recent exposure, were assessed in 587 women 47–74 years of age. We 
assessed their cognitive function 5 years later using validated telephone interviews.
re s u l t s: Mean ± SD lead levels in tibia, patella, and blood were 10.5 ± 9.7 µg/g bone, 12.6 ± 
11.6 µg/g bone, and 2.9 ± 1.9 µg/dL, respectively, consistent with community-level exposures. In 
multivariable-adjusted analyses of all cognitive tests combined, levels of all three lead biomarkers 
were associated with worse cognitive performance. The association between bone lead and letter 
fluency score differed dramatically from the other bone lead-cognitive score associations, and exclu-
sion of this particular score from the combined analyses strengthened the associations between 
bone lead and cognitive performance. Results were statistically significant only for tibia lead: one 
SD increase in tibia lead corresponded to a 0.051-unit lower standardized summary cognitive score 
(95% confidence interval: –0.099 to –0.003; p = 0.04), similar to the difference in cognitive scores 
we observed between women who were 3 years apart in age.
co n c l u s i o n s: These findings suggest that cumulative exposure to lead, even at low levels experi-
enced in community settings, may have adverse consequences for women’s cognition in older age.
key w o r d s : aging, blood lead, cognitive function, epidemiology, KXRF bone lead, women. 
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the women have completed mailed question-
naires every 2 years. To date, the study has 
maintained follow-up of over 90% of the 
original participants.
Our study population came from two sub-
samples of the NHS cohort that had previously 
been evaluated for lead exposure. The first was 
a sample of women participating in a case–
control study of lead exposure and hyperten-
sion (Korrick et al. 1999). We invited women 
to take part in this study if they lived in the 
greater Boston, Massachusetts, metro  politan 
area; did not have a history of major, chronic 
disease; and were not obese (body mass index 
≥ 29 kg/m2). Women who remained free of 
major, chronic disease from 1990 to 1994 were 
invited to participate as controls, and women 
who first reported a diagnosis of hyper  tension 
between 1990 and 1994 were invited to partici-
pate as cases. Controls were frequency matched 
to cases by 5-year age groups. In total, between 
1993 and 1995, 301 NHS participants agreed 
to participate and attended our outpatient 
General Clinical Research Center (GCRC), 
where they under  went the study evaluation, 
including measurement of their lead exposure.
The women in the second sample were 
originally recruited for a cohort study of lead 
exposure and osteoporosis. Similar eligibility 
criteria used for controls in the hypertension 
study applied here, with participants being 
free of chronic diseases during the recruitment 
period from 2000 to 2004. In total, 320 NHS 
participants attended our outpatient GCRC 
for evaluation including lead exposure assess-
ment. In both studies of lead exposure, we 
measured lead content in blood and in both 
cortical and trabecular bone.
Cognitive assessments occurred from 1995 
to 2005. Of the 621 women who participated 
in the lead exposure studies, 6 had died and 
3 were too ill to participate in a cognitive 
assessment. We were unable to contact 17. 
Of those remaining, 8 (1.3%) declined par-
ticipation. Thus, 587 women had cognitive 
assessments. Our analyses of tibia and patella 
bone lead included, respectively, all (587) and 
nearly all (586) of these women; 581 women 
had valid blood lead measurements and were 
included in analyses of blood lead and cogni-
tive function.
Lead exposure assessment. Participants vis-
ited the outpatient GCRC of the Brigham 
and Women’s Hospital for measurement of 
lead content in their bone by K-X-ray fluo-
rescence (KXRF), a non  invasive technique 
for measuring skeletal lead content that can 
distinguish among very low lead burdens 
(Burger et al. 1990). The KXRF instrument 
provides an unbiased estimate of bone lead 
levels normalized to bone mineral content 
and expressed as micrograms of lead per gram 
of bone mineral. The instrument also pro-
vides an estimate of the uncertainty for each 
measurement equivalent to the standard devia-
tion of repeated measurements. Negative esti-
mates of bone lead concentrations may occur 
for lead values close to zero. Use of all point 
estimates without imposition of a minimum 
detectable limit has been identified as the most 
appropriate method of using these data in epi-
demiologic studies (Kim et al. 1995).
Bone lead measurements were made at 
each woman’s mid  tibial shaft and patella. 
These sites are targets for bone lead research 
because the tibia consists mainly of cortical 
bone, and the patella of trabecular bone. The 
half-life of lead in trabecular bone varies by 
age and previous exposure, but in a cohort of 
older men, it has been estimated to be 8 years, 
whereas the half-life of lead in cortical bone is 
on the order of decades (Kim et al. 1997). 
When we began measuring the women’s 
bone lead, we used an instrument developed 
by ABIOMED (Danvers, MA). A technical 
description and validity specifications of this 
instrument have been published elsewhere 
(Aro et al. 2000; Burger et al. 1990; Hu et al. 
1990). In 1999, we replaced our prototype 
ABIOMED instrument with an upgraded 
instrument designed to improve measurement 
precision, with changes in the cadmium radia-
tion source, adjustments to the geometry of 
the measurement procedure, and upgrades 
in both the software and specific hardware 
components of the system (Aro et al. 1994). 
Intercalibration data from persons who were 
meas  ured on both instruments demonstrated 
a linear relationship between the two measure-
ments with a slope of 0.87. Using this correc-
tion factor, we are able to combine data from 
our prototype and upgraded KXRF machines 
(Nie et al. 2008). To reduce the impact of any 
additional scaling differences in these readings 
on our epidemiologic analyses, we included in 
all of our bone lead regression models a term 
for lead substudy source, which effectively 
adjusts for instrument, because women from 
the hypertension substudy were assessed on 
the ABIOMED instrument and women from 
the osteoporosis study were assessed on the 
upgraded instrument.
We collected samples of blood in trace-
metal–free tubes (with EDTA) and analyzed 
them for whole blood lead using graph-
ite furnace atomic absorption with Zeeman 
background correction (ESA Laboratories, 
Chelmsford, MA). The instrument was cali-
brated with National Institute of Standards 
and Technology (NIST) Standard Reference 
Material (SRM) 955a, lead in blood (NIST, 
Gaithersburg, MD), after every 20 samples. 
Ten percent of samples were run in dupli-
cate; at least 10% of the samples were controls 
and 10% were blanks. In tests on reference 
samples from the Centers for Disease Control 
and Prevention (Atlanta, GA) precision (coef-
ficient of variation) ranged from 8% for 
lead concentrations of 10–30 µg/dL to 1% 
for higher concentrations. Compared with 
an NIST target of 5.7 µg/dL, 24 measure-
ments by this method gave a mean ± SD of 
5.3 ± 1.23 µg/dL. Eighteen percent of women 
in our study had blood lead levels below the 
minimum detection limit of 1.0 µg/dL; we 
recoded these values to be 1 µg/dL divided by 
the square root of 2 (0.71 µg/dL).
Cognitive function assessment. Cognitive 
testing occurred as part of several sub  studies, 
although overall methods were identical in all 
participants. Of the 587 women included in 
our analyses, 72 (12%) were tested as part of 
a large-scale study of cognition that began in 
1995 of NHS participants ≥ 70 years of age; 
14 (2%) were tested in 2002 and 2004 as part 
of a study of cognition in “younger” older 
women and a study of Parkinson disease; and 
the remaining 501 women were tested during 
2004–2005 to assess those in the lead study 
who had not been evaluated as part of these 
other studies. On average, cognitive assessments 
took place 5 years (25th to 75th percentile, 
2–9.8 years) after lead exposure assessments.
All cognitive testing was administered 
using validated telephone interviews con-
ducted by trained nurses. When testing began 
in 1995, we administered only the Telephone 
Interview for Cognitive Status (TICS; n = 587) 
(Brandt et al. 1988), a test of global cogni-
tion that is modeled on the Mini-Mental State 
Examination (MMSE) and evaluates functions 
such as orientation, registration, and immedi-
ate verbal memory (Folstein et al. 1975). A 
score < 31 on the TICS indicates cognitive 
impairment. We gradually added other tests to 
the battery; thus the sample size differs slightly 
across the cognitive tests. These tests include 
delayed recall of the 10-word list (n = 569) 
from the TICS to assess delayed verbal mem-
ory; the East Boston Memory Test (EBMT; 
n = 582) to assess immediate and delayed para-
graph recall (Albert et al. 1991; Scherr et al. 
1988); category fluency (n = 582) in which 
participants were asked to name as many ani-
mals as they could in 1 min (Goodglass and 
Kaplan 1983); and the digit span backwards 
test (n = 566), to assess working memory and 
attention (Lezak 1995). The women tested dur-
ing 2004–2005 and in one of the small studies 
were slightly younger than the women partici-
pating in the large-scale study of cognition; to 
better discriminate the cognitive abilities of 
these younger women, we added two tests to 
their assessment battery. For the alphabetizing 
span test (n = 508), another test of working 
memory and attention, women were asked 
to recall in alphabetical order an increasingly 
longer list of unordered words (Craik 1990). 
We also tested letter fluency (n = 511) by ask-
ing them to name as many words beginning 
with “f” as they could in 1 min (Lezak 1995). 
For analyses, we calculated a composite score Weuve et al.
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of verbal memory (n = 568), a strong predictor 
of Alzheimer disease (AD) development (Linn 
et al. 1995; Tabert et al. 2006), by averaging 
the z scores of the immediate and delayed recall 
of both the EBMT and the TICS 10-word list 
for all women who took these tests.
Previously, we extensively evaluated the reli-
ability and validity of our telephone assessment 
procedure. Interviewers were highly consistent 
with each other in their scoring; we recorded 
all interviewers as they adminis  tered the cogni-
tive battery, and then each interview was eval-
uated by multiple interviewers. Correlations 
between interviewers’ score assignments on 
any given test exceeded 0.95. We also found 
high reliability of test performance among 
35 women given the TICS twice 31 days apart 
(Pearson r = 0.7). In a vali  dation study we con-
ducted among 61 women from the Religious 
Orders Study (Bennett et al. 2002) of similar 
age and educational status to our participants, 
we found a correlation of 0.81 between overall 
performance on our telephone interview and 
overall performance on an in-person interview. 
As with performance on in-person assessments, 
performance on our telephone assessment 
strongly predicts dementia diagnosis. In our 
clinical validation study, over 3 years, the risk 
of dementia was 8–12 times higher for women 
with poor general cognition and 26 times 
higher for those with poor episodic memory on 
our telephone interview.
Statistical analysis. We performed 
separate analyses for each of the three lead 
biomarkers. For ease in comparing results for 
the different cognitive tests, we used each cog-
nitive test’s z score, computed from the means 
and SDs in our study population.
We examined performance on the indi-
vidual test z scores and verbal memory score, 
using multiple linear regression to estimate 
the mean difference in standardized cogni-
tive test score (z score) per SD increment in 
levels of each of the three lead biomarkers. To 
summarize the overall association of each lead 
biomarker with cognitive performance, we 
used generalized estimating equation (GEE) 
models, initially treating the eight z scores as 
correlated repeated measures of cognitive func-
tion (Lefkopoulou et al. 1989). If all cognitive 
test scores reflect the same under  lying phe-
nomenon, these GEE models provide effect 
estimates that are more precise than those 
from the models of the individual test scores. 
These models also are able to accommodate 
missing cognitive scores, such as when a par-
ticipant was not administered a test in the bat-
tery. For each lead biomarker, we fit a GEE 
model that simultaneously regressed the eight 
cognitive test z scores on the biomarker and 
covariates, producing a summary estimate of 
the mean difference in standardized cognitive 
test score per SD increment in lead biomarker. 
We allowed the working matrix of correla-
tions between cognitive scores to be unstruc-
tured. In model fitting, we assumed that the 
lead biomarker–cognitive score association 
was the same across all cognitive tests (com-
mon exposure effect assumption). We tested 
this assumption by fitting a GEE model, as 
described above, but which also included cross-
product terms between the lead biomarker of 
interest and indicators for each cognitive test 
(except for an arbitrarily chosen referent, the 
EBMT-immediate recall). A generalized score 
test with 7 degrees of freedom corresponds to 
the cross-product terms combined. Large val-
ues of the generalized score test indicate sub-
stantial deviation from the common exposure 
effect assumption, meaning that at least one of 
the cognitive tests differs significantly from the 
others in its association with lead and suggest-
ing reconsideration of the individual cognitive 
tests included in the model.
We adjusted all models for factors evalu-
ated near the time of the lead exposure assess-
ment that may confound the association 
between lead and cognition or, to improve 
analytical precision, were strongly associated 
with cognition in previous work. These factors 
included age at lead exposure assessment, age 
squared, education (registered nurse degree, 
bachelor’s degree, advanced graduate degree), 
husband’s education (high school diploma or 
less, college degree, advanced graduate degree; 
an additional measure of socioeconomic 
status), alcohol consumption (measured by 
food frequency questionnaire as none, up to 
Table 1. Levels of lead exposure biomarkers (mean ± SD) by women’s characteristics.
  Lead biomarkera
  Tibia  Patella  Blood
Characteristic  No. (%)b  Lead (µg/g)  p-Value  Lead (µg/g)  p-Value  Lead (µg/dL)  p-Value
Age at lead exposure assessment (years)
  47–54  92 (16)  10.6 ± 8.3   0.0004  14.6 ± 11.0   0.001  2.6 ± 2.0   0.4
  55–59  133 (23)  9.0 ± 8.7     10.7 ± 10.2     2.8 ± 1.9 
  60–64  184 (31)  9.1 ± 9.4      11.5 ± 10.9     3.0 ± 1.9    
  65–69  138 (24)  12.8 ± 10.4     13.0 ± 12.3     3.0 ± 1.6 
  70–74  40 (7)  14.0 ± 12.8     18.5 ± 15.8     3.1 ± 2.2 
Education
  Registered nurse diploma  340 (58)  11.0 ± 9.9   0.2  13.6 ± 11.1   0.05  3.0 ± 2.0    0.3
  Bachelor’s degree  160 (27)  10.4 ± 8.9      10.8 ± 12.4      2.7 ± 1.6 
  Master’s or doctorate degree  87 (15)  9.0 ± 10.5     12.4 ± 11.9     2.9 ± 1.9 
Husband’s education
  High school or less  137 (23)  12.2 ± 10.5   0.06  15.1 ± 13.2   0.01  3.2 ± 2.3    0.06
  College education  313 (53)  9.9 ± 9.9      12.2 ± 11.5      2.8 ± 1.7 
  No longer married or unknown  137 (23)  10.4 ± 8.5     11.3 ± 9.8     2.9 ± 1.7 
Smoking status
  Never  234 (40)  9.8 ± 9.2   0.3  11.3 ± 10.8   0.07  2.7 ± 1.8    0.01
  Past  308 (52)  10.9 ± 10.2     13.6 ± 12.4      3.0 ± 2.0 
  Current  45 (8)  11.6 ± 9.4     12.9 ± 9.2     3.6 ± 1.6 
Alcohol consumption, long-term mean (g/day)
  < 1  141 (24)  9.4 ± 9.1   0.3  12.2 ± 11.2   0.6  2.5 ± 1.5    0.01
  1–4  200 (34)  10.6 ± 9.9     12.4 ± 11.5      2.9 ± 2.0 
  5–14  155 (26)  10.9 ± 9.8     13.1 ± 13.1     3.1 ± 2.1 
  ≥ 15  69 (12)  12.2 ± 10.6     14.2 ± 10.3     3.4 ± 1.7 
Energy expended on regular physical activity (MET-hr/week)
  < 16  284 (48)  11.0 ± 8.8    0.2  12.3 ± 11.2    0.5  2.9 ± 1.8    0.6
 ≥  16  300 (51)  10.0 ± 10.4     12.9 ± 12.1     2.9 ± 2.0 
Postmenopausal hormone use
  Premenopausal  44 (7)  10.3 ± 8.2     13.5 ± 11.8     2.3 ± 1.5 
  Postmenopausal
    Never used   140 (24)  11.6 ± 10.1   0.5  12.5 ± 12.5   0.2  3.6 ± 2.3   < 0.0001
    Used in the past  222 (38)  9.9 ± 10.9     11.4 ± 12.1      3.1 ± 1.8  
    Currently use  181 (31)  10.5 ± 8.2     14.0 ± 10.1     2.2 ± 1.4 
Aspirin use (times/week)
  < 3   460 (78)  9.9 ± 9.3    0.02  11.8 ± 11.0    0.001  2.9 ± 1.8    0.1
 ≥  3   74 (13)  12.7 ± 12.0     16.5 ± 14.8     3.2 ± 2.6 
Ibuprofen use
  No  435 (74)  10.4 ± 10.0    0.6  12.5 ± 11.4    0.7  2.9 ± 1.9    0.8
  Yes  152 (26)  10.9 ± 8.9     13.0 ± 12.3     2.9 ± 2.0 
Vitamin E use
  No  322 (55)  10.9 ± 9.9    0.4  13.4 ± 12.3    0.2  3.0 ± 2.0    0.1
  Yes  215 (37)  10.1 ± 10.0     11.9 ± 11.1     2.8 ± 1.7 
TICS score < 31
  No  565 (96)  10.3 ± 9.5    0.006  12.3 ± 11.4    0.001  2.9 ± 1.8    0.02
  Yes  22 (4)  16.1 ± 13.3     20.4 ± 14.7     3.8 ± 2.7 
MET-hr, metabolic equivalent-hours. 
ap-Values for each trait and lead biomarker correspond to the F test of the overall association between the trait and the 
lead biomarker. bWomen with bone lead assessments (total n = 587); denominators for patella lead, blood lead, alcohol 
intake, physical activity, aspirin use, and vitamin E use are slightly smaller.Lead exposure and cognition in older women
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1 drink/week, 2–6 drinks/week, ≥ 1 drink/
day), smoking (current, past, never), regular 
pattern of physical activity (energy expendi-
tures computed from responses on a leisure 
activity frequency questionnaire, and divided 
into tertiles), aspirin use (non  user, 1 time/
month to 2 times/week, ≥ 3 days/week), ibu-
profen use (non  user, current user), vitamin E 
supplementation (yes, no), menopausal sta-
tus (yes, no) and post  menopausal hormone 
use (never, past, current). We also included 
terms for age at cognitive assessment, lead 
sub  study, and cognitive sub  study. In separate 
models, we further adjusted for vascular and 
mental health factors that might be either 
confounders or intermediates in the causal 
pathway between lead exposure and cogni-
tive function, including high blood pressure, 
anti  hypertensive medication use, poor mental 
health on the mental health scale of the Short 
Form-36, and anti  depressant use. (We did 
not adjust for other factors such as coronary 
heart disease and diabetes, because very few 
women in this relatively healthy subsample 
reported having these conditions.)
We conducted all analyses using SAS ver-
sion 9 (SAS Institute Inc., Cary, NC), using 
PROC GENMOD to fit the GEE models. 
We used p < 0.05 as the level of statistical 
significance.
This study was approved by the institu-
tional review boards of the Brigham and 
Women’s Hospital, the Harvard School of 
Public Health, and the University of Michigan. 
Study participants gave their written consent to 
participate in the studies of lead exposure and 
gave their verbal consent to participate in the 
cognitive portions of the study at the time of 
their cognitive assessment.
Results
At the time of their lead assessments, the 
women in our study were 47–74 years of age 
(mean, 61 years). Nearly all (99%) identified 
themselves as non-Hispanic white. Typical of 
a non  occupationally exposed population, they 
had relatively low concentrations (mean ± SD) 
of lead in their tibia (10.5 ± 9.7 µg/g), patella 
(12.6 ± 11.6 µg/g), and blood (2.9 ± 1.9 µg/
dL). These levels were about half of levels 
observed among a cohort of slightly older men 
(mean age, 67 years) also living in the greater 
Boston area (Hu et al. 1996). Lead levels in the 
two bone sites were more strongly correlated 
with each other (Spearman r = 0.44) than with 
blood lead (r = 0.18 and 0.23 for patella and 
tibia lead, respectively). As observed previously 
(Korrick et al. 2002), lead biomarker levels 
were higher among women who were older, 
had less formal education, were current or 
former smokers, and consumed more alcohol 
(Table 1). Among these “young old” women, 
only 22 (4%) scored < 31 on the TICS, indi-
cating potential cognitive impairment, and lead 
biomarker levels were markedly higher in these 
women, by 5.4 µg/g, 8.1 µg/g, and 0.9 µg/dL 
in tibia, patella, and blood, respectively.
After adjusting for potential confounding 
factors, higher levels of the lead biomarkers 
were generally associated with worse per-
formance on the individual cognitive tests, 
although none of these negative associations 
reached statistical significance (Figure 1). The 
inverse associations between lead exposure 
and cognitive function tended to be more 
pronounced for tibia lead than for the other 
two lead biomarkers. Of the negative associa-
tions for tibia lead, the strongest corresponded 
to the digit span backwards (p = 0.19) and the 
alphabetizing span tests (p = 0.23), both tests 
of attention and working memory.
Unexpectedly, higher levels of bone lead 
were associated with better performance 
on the letter fluency test, significantly so 
for patella lead (p = 0.05) (Figure 1). This 
discrepancy also appeared in results from 
GEE models in which we tested the com-
mon exposure effect assumption. These analy-
ses revealed hetero  geneity in the associations 
between bone lead and the cognitive tests, 
especially for patella lead, where the hetero-
geneity was statistically significant (p = 0.02). 
In particular, the association of patella lead 
with letter fluency test score was significantly 
different from the other patella lead–cogni-
tive test associations (p = 0.006). Therefore, 
in addition to fitting GEE models that used 
all cognitive scores, we fit GEE models that 
excluded letter fluency scores. 
Results from the GEE models that included 
all cognitive tests indicated that all three 
lead biomarkers were associated with worse 
overall cognitive function, although none of 
these associations was statistically significant 
(Table 2). However, when we excluded the let-
ter fluency test from these models, these inverse 
Figure 1. Adjusted mean difference (95% CI) in specific standardized cognitive test scores per SD incre-
ment in lead biomarker. Values are adjusted for age and age-squared at lead assessment, age at cognitive 
assessment, education, husband’s education, alcohol consumption, smoking status, physical activity, aspi-
rin use, ibuprofen use, use of vitamin E supplements, menopausal status and postmenopausal hormone 
use, lead substudy source, and cognitive substudy source. Numbers left of bars indicate p-values.
aAverage of z scores from the immediate and delayed recall of both the EBMT and the TICS 10-word list. 
TICS
Digit span backwards
Tegory fluency (animal naming)
Alphabetizing span
Letter fluency (”f” naming)
Verbal memory compositea
–0.20 –0.16 –0.12 –0.08 –0.04 0.00 0.04 0.08 0.12 0.16 0.20 0.24
0.29
0.63
0.19
0.19
0.25
0.50
0.23
0.73
0.85
0.24
0.85
0.48
0.82
0.05
0.72
0.35
0.61
1.00
Mean difference
Tibia bone lead (SD, 10 µg/g)
Patella bone lead (SD, 12 µg/g)
Blood lead (SD, 2 µg/dL)
Table 2. Adjusteda mean difference (95% CI) in overall standardized cognitive test score per SD increment 
in lead biomarker.
  All cognitive tests   All cognitive tests except letter fluency
  Mean difference (95% CI)  p-Value  Mean difference (95% CI)  p-Value
Per SD increment in lead biomarker
  Tibia bone lead (SD, 10 µg/g)  –0.040 (–0.085 to 0.004)  0.08  –0.051 (–0.099 to –0.003)  0.04
  Patella bone lead (SD, 12 µg/g)  –0.012 (–0.056 to 0.033)  0.61  –0.033 (–0.080 to 0.014)  0.17
  Blood lead (SD, 2 µg/dL)  –0.015 (–0.069 to 0.039)  0.59  –0.016 (–0.071 to 0.039)  0.57
Per year in age at cognitive  –0.018 (–0.029 to –0.008)  0.003  –0.017 (–0.028 to –0.007)  0.002 
assessmentb
aBased on GEE models adjusted for age and age-squared at lead assessment, age at cognitive assessment, education, 
husband’s education, alcohol consumption, smoking status, physical activity, aspirin use, ibuprofen use, use of vitamin 
E supplements, menopausal status and postmenopausal hormone use, lead substudy source, and cognitive substudy 
source. bAdjusted for education, husband’s education, lead substudy source, and cognitive substudy source. Weuve et al.
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associations became more pronounced, most 
markedly for patella bone lead. Notably, the 
association of tibia lead with overall cognitive 
function became statistically significant; for 
each SD increment in tibia bone lead concen-
tration (10 µg/g), overall standardized cognitive 
scores were 0.051 units lower [95% confidence 
interval (CI), –0.099 to –0.003; p = 0.04]. 
To help interpret this finding, we contrasted 
the association of tibia lead with cognition to 
the association we found for age and cogni-
tion. Specifically, the 0.051-unit decrement in 
standardized cognitive score was equivalent to 
the difference in scores we observed between 
women in our study who were about 3 years 
apart in age. In these models, associations of 
both bone lead biomarkers with overall cogni-
tive function were stronger than associations 
corresponding to blood lead.
Results remained unchanged when we 
further adjusted for potential vascular and 
mental health intermediates. 
Discussion
In this large study of healthy “young old” 
women, cumulative community-level expo-
sure to lead, measured by concentration of 
lead in tibia bone, was associated with signifi-
cantly worse overall performance on cognitive 
function tests. Specifically, the average decre-
ment in cognitive test scores we observed for 
each SD increase in tibia lead corresponded 
to the decrement in scores we observed for 
each 3-year increase in age among women in 
our study. 
Levels of two other lead biomarkers—
patella lead and blood lead—were also associ-
ated with worse cognitive function, but these 
associations were not significant. This pattern 
of association suggests that lead exposures in 
the distant past may be more important than 
relatively recent exposures in influencing cog-
nitive function in these women, because tibia 
lead levels measure cumulative exposures over 
the past decades, in contrast to the more recent 
exposures measured by patella and blood 
lead levels (Hu et al. 2007). Although tibia 
lead assessments cannot distinguish between 
chronic low-dose exposures and high exposures 
during a critical period in the past (Shih et al. 
2007), chronic low-dose exposures likely pre-
vailed among the women in this study, who 
probably incurred most of their exposures to 
lead from gasoline emissions and consumer 
products beginning in childhood and lasting at 
least through the 1980s, when these products 
were phased out in the United States. 
The only large-scale study to report on 
lead’s association with cognition among older 
women occurred in the Study of Osteoporotic 
Fractures. Investigators cross-sectionally exam-
ined urban- and rural-dwelling women and 
found that higher blood lead levels predicted 
worse performance on several cognitive tests 
(Muldoon et al. 1996), although this associa-
tion was present only among the rural-dwell-
ing women. The reason for these restricted 
findings is unclear. One possibility, which 
is indirectly supported by our data, is that 
the measure of lead exposure—blood lead 
level—did not adequately capture the range 
of relevant exposures experienced by these 
U.S.-based women.
Numerous studies of adults with occupa-
tional exposures to lead have found adverse 
associations between current blood lead level 
and cognitive outcomes. Nonetheless, many of 
these studies also have found that meas  ures of 
cumulative dose (e.g., serial blood lead meas-
urements) generally are more strongly asso-
ciated than current blood lead with adverse 
cognitive outcomes (Shih et al. 2007). These 
cohorts are characterized by high past and 
current exposures, with mean current blood 
lead levels often exceeding 25 µg/dL. In con-
trast, patterns of exposure among community- 
exposed adults in the United States reflect 
high past exposures followed by low current 
exposures, making current blood lead level a 
potentially less sensitive measure than cumu-
lative exposure measures for evaluating the 
relation between lead exposure and cognitive 
aging in this population. This notion is sup-
ported by findings from studies of two com-
munity-based cohorts that suggest apparent 
effects of cumulative but not current low-level 
lead exposure on poor cognition and cognitive 
decline. In > 400 men (mean age, 67 years) 
participating in the Normative Aging Study, 
bone lead levels were associated with signifi-
cantly steeper decline over a 3.5-year interval 
on the MMSE (Weisskopf et al. 2004) and 
three visuo  spatial tests (Weisskopf et al. 2007). 
Blood lead levels were cross-sectionally associ-
ated with performance only on a vocabulary 
test (Weisskopf et al. 2007) and the MMSE 
(Weuve et al. 2006). Similarly divergent find-
ings for bone and blood lead initially emerged 
from a study of 994 older adults participat-
ing in the Baltimore Memory Study, in which 
tibia lead levels—but not blood lead levels—
were associated with worse performance on all 
seven cognitive domains tested; however, these 
associations were substantially attenuated and 
no longer significant upon further adjustment 
for education, race/ethnicity and wealth (Shih 
et al. 2006), closer to the analyti  cal framework 
of our study. A third study of 533 young adults 
(mean age, 24 years) found significant asso-
ciations between living next to a lead smelter 
during childhood and performance on several 
cognitive tests (Stokes et al. 1998).
Few large-scale studies of cumulative lead 
exposure and cognition in older adults have 
included women, and none has reported results 
that are specific to women (Shih et al. 2007). 
The present study indicates that cumulative 
lead exposure may adversely affect cognitive 
aging even among women, whose exposure 
to lead is typically lower than that of men. 
This association has important consequences 
for public health, because impaired cognitive 
function is a strong risk factor for dementia 
(Bennett et al. 2002; Kawas et al. 2003; Morris 
et al. 2001) and because women have a higher 
lifetime risk than men of developing dementia 
(Andersen et al. 1999; Hebert et al. 2001; Ott 
et al. 1998; Seshadri et al. 1997).
More generally, although lead levels in the 
environment have fallen dramatically in the past 
two decades, many older adults have endured 
protracted exposures to lead in the preceding 
decades and have accumulated lead in their 
skeletons. Together with previous findings, our 
results have important implications for the cog-
nitive functioning of this growing population of 
older adults. In the United States, the popula-
tion of persons ≥ 65 years of age is projected 
to double between 2000 and 2030 (He et al. 
2005), leading to a rapid rise in the number of 
individuals afflicted with age-related demen-
tia. This phenomenon will likely be echoed 
throughout the globe (Ferri et al. 2005). One 
model has forecasted that a broadly applied 
intervention, such as a regulatory intervention 
that delays the onset of AD by 2 years, could 
reduce the number of prevalent cases in the 
United States by about 2 million over a 40-year 
interval (Brookmeyer et al. 1998). Thus, even if 
lead has a subtle effect in accelerating cognitive 
aging, given the pervasiveness of lead exposure 
in the United States and globally, widespread 
reductions in this exposure could have a sub-
stantial impact on the burden of cognitive 
impairment in the population.
Chronic, low-dose exposure to lead may 
adversely affect cognitive functioning in older 
age through several actions. Chiefly, lead can 
damage and eventually kill neurons through its 
oxidative toxicity, whereby lead both induces 
oxidative stress (Acharya and Acharya 1997; 
Adonaylo and Oteiza 1999b) and impedes 
responses to oxidative stress (Adonaylo and 
Oteiza 1999a; Ercal et al. 1996) in the brain. 
Oxidative stress, in turn, appears to be integral 
to the pathogenesis of cognitive decline and 
dementia (Andersen 2004; Markesbery and 
Lovell 2007). Lead also accumulates in neural 
mitochondria, where it eventually generates 
the abnormal release of calcium and induces 
apoptotic cell death (Anderson et al. 1996; 
Fox et al. 1997; He et al. 2000; Silbergeld 
1992). Chronic exposure to lead is followed 
by astrogliosis in the hippocampus, indicating 
neuronal injury or death in a region that is crit-
ical for learning and memory function (Selvin-
Testa et al. 1994). Acutely, lead also appears 
to interfere with calcium-dependent enzymes 
(Toscano and Guilarte 2005) as well as cholin-
ergic, glutaminergic, and dopaminergic neuro-
transmitter systems—all integral components 
of cognition (Cory-Slechta 1995).Lead exposure and cognition in older women
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Several limitations of our study warrant 
consideration. It is unlikely that our study find-
ings directly reflect the acute cognitive effects of 
lead because current exposure levels, indicated 
by blood lead levels, were distributed over a 
very limited range. However, as a result of 
these limited current exposures, our study pro-
vides further evidence that past and cumulative 
exposures—apart from current exposures—
may have chronic cognitive effects.
Previous studies have identified inverse 
associations between cumulative lead expo-
sure and visuo  spatial ability (Barth et al. 
2002; Schwartz et al. 2000; Shih et al. 2006; 
Stewart et al. 1999; Weisskopf et al. 2007), 
but we were not able to explore this asso-
ciation in our study due to practical limita-
tions in administering the cognitive battery 
by telephone. However, telephone testing has 
important advantages and enabled us to maxi-
mize recruitment into the cognitive study.
In addition, the GEE analysis was useful 
for summarizing our results and effectively 
optimized the precision of our effect estimates. 
Use of these models is contingent on reason-
ably homogeneous associations between lead 
and cognitive function for all cognitive tests 
included; however, the puzzling association of 
higher patella lead with better performance on 
the letter fluency test violated this assumption. 
This appears to be a unique finding, likely due 
to chance. Alternatively, this finding may hint 
that lead-induced cognitive impairments in 
older age overlap with those of AD. In AD, 
deficits in semantic fluency (e.g., category flu-
ency) are common, whereas deficits in phone-
mic fluency (e.g., letter fluency) are not (Henry 
et al. 2004; Rascovsky et al. 2007). However, 
this explanation requires confirmation from 
future research.
Our single assessments of cognitive func-
tion do not directly capture change in cogni-
tive function, nor do they evaluate dementia 
status. The women in our study were in their 
50s and 60s at the time of their lead assess-
ments, and were 5 years older, on average, 
when cognitive testing occurred. At these 
ages, dementia is still relatively rare (Rocca 
et al. 1998), but subtle decrements in cogni-
tion may be considered a pre  clinical stage of 
the condition, preceding it by many years 
(Elias et al. 2000; Kawas et al. 2003; Morris 
et al. 2001). Nonetheless, the direct evalua-
tion of lead exposure in relation to cognitive 
change is of great interest, and repeated cog-
nitive assessments will be conducted.
It is possible that our results were influ-
enced by selection processes, although the 
direction of the ensuing bias, if any, is not 
altogether clear. About half of the participants 
were women from a case–control study of 
hyper  tension. Because lead exposure appears 
to be related to hypertension (Navas-Acien 
et al. 2007), it is possible that we overestimated 
lead’s adverse cognitive effects if cognition, too, 
was related to participation. Nonetheless, for 
our cognitive study, the cases from the hyper-
tension study represented only 14% of par-
ticipants. Conversely, the women in our study 
were healthy at enrollment, free of chronic dis-
eases (except hypertension alone for cases); they 
also had low exposures to lead. Thus, again 
assuming that cognition was related to partici-
pation, then the over  representation of women 
who had both excellent cognition and low 
exposures to lead might have led us to under-
estimate lead’s adverse cognitive effects. 
Finally, as in any observational study, our 
results could be confounded by unmeasured 
or mismeasured factors. The NHS cohort is 
fairly well-characterized, however, and is more 
homogeneous in terms of occupational and 
socio  economic factors than most community-
based cohorts. In addition, our results were 
robust to adjustment for numerous potential 
confounders, including education and hus-
band’s education, indicators of socio  economic 
status. It remains possible that the lead expo-
sure during adulthood that we measured 
directly via tibia lead is a proxy for lead expo-
sures and its consequences endured during 
childhood and, therefore, that the association 
between tibia lead and cognition mis  specifies 
the importance of adult exposures. Although 
our data are insufficient to satisfactorily con-
firm or refute this possibility, we examined 
our findings in the presence and absence of 
adjustment for educational attainment—a 
blunt indicator of the consequences of child-
hood lead exposure—and the findings were 
unchanged.
In summary, in this study of 587 “young 
old” women who had community-level expo-
sures to lead, higher levels of tibia lead (a 
meas  ure of cumulative dose) were significantly 
associated with worse overall performance on 
a series of cognitive tests. In contrast, asso-
ciations between a measure of recent lead 
exposure and cognition were weaker and not 
significant. This pattern of results suggests 
that, even in the absence of substantial current 
exposures to lead, chronic, low-level historical 
exposures to lead may have adverse conse-
quences for the cognitive aging of women and 
thus merit further research.
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